Quince Therapeutics Stock (NASDAQ:QNCX)

Forecast Financials Chart

Previous Close

$1.86

52W Range

$0.51 - $2.45

50D Avg

$1.39

200D Avg

$1.43

Market Cap

$84.12M

Avg Vol (3M)

$381.12K

Beta

0.96

Div Yield

QNCX Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 09, 2019

Website

QNCX Performance

QNCX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-57.28M	$-34.62M	$-52.02M
Net Income	$-56.83M	$-31.39M	$-51.66M
EBITDA	$-57.28M	$-31.26M	$-52.02M
Basic EPS	$-1.31	$-0.84	$-1.54
Diluted EPS	$-1.31	$-0.84	$-1.54

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 13Nov 07, 13 | 5:00 PM

Q2 13Aug 06, 13 | 5:00 PM

Q1 13May 09, 13 | 5:00 PM

Peer Comparison

Ticker	Company
PMVP	PMV Pharmaceuticals, Inc.
RAPT	RAPT Therapeutics, Inc.
LENZ	LENZ Therapeutics, Inc.
UNCY	Unicycive Therapeutics, Inc.
HSCS	Heart Test Laboratories, Inc.